Literature DB >> 24035783

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.

Alan S Wayne1, Sergio Giralt, Nicolaus Kröger, Michael R Bishop.   

Abstract

Despite advances in hematopoietic stem cell transplantation (HSCT) for the treatment of hematologic malignancies, relapse remains the leading cause of death after transplant. Biologic and clinical investigations are needed to combat this primary cause of death after transplantation. The National Cancer Institute held international workshops in 2009 and 2012 to help address this problem. Three major initiatives for coordinated research were proposed: 1) To establish multicenter networks for basic, translational, epidemiologic and clinical research; 2) To establish a network of biorepositories for the collection of samples before and after HSCT to aid in laboratory and clinical studies; and 3) To refine, implement and study proposed definitions for disease-specific response and relapse and for monitoring of minimal residual disease. The workshop in 2012 also featured nine presentations, summaries of which follow in three manuscripts.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic; Autologous; Hematologic malignancies; Hematopoietic stem cell transplantation; Post-transplant relapse

Mesh:

Year:  2013        PMID: 24035783      PMCID: PMC3880421          DOI: 10.1016/j.bbmt.2013.08.016

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Authors:  Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-07-29       Impact factor: 6.860

Review 2.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.

Authors:  Steven Z Pavletic; Shaji Kumar; Mohamad Mohty; Marcos de Lima; James M Foran; Marcelo Pasquini; Mei-Jie Zhang; Sergio Giralt; Michael R Bishop; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-04-24       Impact factor: 5.742

Review 3.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

Authors:  Edwin P Alyea; Daniel J DeAngelo; Jeffrey Moldrem; John M Pagel; Donna Przepiorka; Michel Sadelin; James W Young; Sergio Giralt; Michael Bishop; Stan Riddell
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-24       Impact factor: 5.742

4.  NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.

Authors:  Mitchell S Cairo; Craig T Jordan; Carlo C Maley; Clifford Chao; Ari Melnick; Scott A Armstrong; Warren Shlomchik; Jeff Molldrem; Soldano Ferrone; Crystal Mackall; Laurence Zitvogel; Michael R Bishop; Sergio A Giralt; Carl H June
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-12       Impact factor: 5.742

5.  NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.

Authors:  Jeffrey S Miller; Edus H Warren; Marcel R M van den Brink; Jerome Ritz; Warren D Shlomchik; William J Murphy; A John Barrett; Hans Jochem Kolb; Sergio Giralt; Michael R Bishop; Bruce R Blazar; J H Frederik Falkenburg
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-10       Impact factor: 5.742

6.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.

Authors:  Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Homer A Macapinlac; Homer Macapintac; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-14       Impact factor: 5.742

7.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

8.  Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.

Authors:  R Handgretinger; G Zugmaier; G Henze; H Kreyenberg; P Lang; A von Stackelberg
Journal:  Leukemia       Date:  2010-10-14       Impact factor: 11.528

9.  NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.

Authors:  Nicolaus Kröger; Ulrike Bacher; Peter Bader; Sebastian Böttcher; Michael J Borowitz; Peter Dreger; Issa Khouri; Eduardo Olavarria; Jerald Radich; Wendy Stock; Julie M Vose; Daniel Weisdorf; Andre Willasch; Sergio Giralt; Michael R Bishop; Alan S Wayne
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-15       Impact factor: 5.742

10.  Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Authors:  T Schroeder; A Czibere; U Platzbecker; G Bug; L Uharek; T Luft; A Giagounidis; F Zohren; I Bruns; C Wolschke; K Rieger; R Fenk; U Germing; R Haas; N Kröger; G Kobbe
Journal:  Leukemia       Date:  2013-01-14       Impact factor: 11.528

View more
  1 in total

Review 1.  Checkpoint inhibitors in AML: are we there yet?

Authors:  Arnab Ghosh; Pere Barba; Miguel-Angel Perales
Journal:  Br J Haematol       Date:  2019-12-06       Impact factor: 8.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.